Who makes Hydration plus N-acetylcisteine?

Hydration plus N-acetylcisteine is developed by Ospedale Misericordia e Dolce.

What development phase is Hydration plus N-acetylcisteine in?

Hydration plus N-acetylcisteine is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

Hydration plus N-acetylcisteine

Ospedale Misericordia e Dolce · FDA-approved active Small molecule Quality 2/100

Hydration plus N-acetylcisteine, marketed by Ospedale Misericordia e Dolce, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from competitors. The primary risk is the potential for increased competition post-patent expiry in 2028.

At a glance

Generic name	Hydration plus N-acetylcisteine
Sponsor	Ospedale Misericordia e Dolce
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Aminophylline and Contrast Induced Nephropathy in Acute Myocardial Infarction (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hydration plus N-acetylcisteine CI brief — competitive landscape report
Hydration plus N-acetylcisteine updates RSS · CI watch RSS
Ospedale Misericordia e Dolce portfolio CI